// App-Quantinova.ai

109 : Identification of good and poor prognosis HPV associated oropharyngeal cancer based on CD103 immune cell expression in patients treated with cetuximab and radiotherapy on TROG 12.01 and De-ESCALaTE randomized trials.

Researchers

Presenter

  • Danny Rischin

Principal Investigators

  • Hisham Mohamed Mehanna

  • Richard J. Young

  • Mathias Bressel

  • Janet Dunn

  • June Corry

  • Tessa Fulton-Lieuw

  • Gulnaz Iqbal

  • Lizbeth M. Kenny

  • Sandro Porceddu

  • Christopher Wratten

  • Max Robinson

  • Benjamin J. Solomon

Medical Centers

  • Division of Cancer Medicine, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia

  • Institute of Head and Neck Studies and Education, University of Birmingham, Birmingham, United Kingdom

  • Research Division, Peter MacCallum Cancer Centre, Melbourne, Australia

  • Centre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne, Australia

  • Warwick Clinical Trials Unit, University of Warwick, Coventry, United Kingdom

  • Genesiscare St Vincent’s Hospital and Department of Medicine, University of Melbourne, Melbourne, Australia

  • Department of Medical Oncology, Royal Brisbane & Women's Hospital, and School of Medicine, University of Queensland, Brisbane, QLD, Australia

  • Department of Medical Oncology, Royal Brisbane & Women's Hospital, and School of Medicine, University of Queensland, Brisbane, QLD, Australia

  • Department of Radiation Oncology, Calvary Mater Hospital and University of Newcastle, Newcastle, Australia

  • Cellular Pathology, Newcastle upon Tyne Hospitals, Newcastle, United Kingdom

  • Department of Medical Oncology and Research Division, Peter MacCallum Cancer Centre and the Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia

Locations

  • Australia

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Oropharyngeal carcinoma

Biomarkers

  • N/A

Drug/Treatment

  • Erbitux

Outcome

  • N/A

Study Design

  • Randomized

  • Multicenteric

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved